Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer Updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years

Peter Iversen Departments of Urology, University of Copenhagen, Rigshospitalet, Copenhagen, DenmarkCorrespondence[email protected]

, MD,

Jan-Erik Johansson Departments of Urology, Örebro University Hospital, Örebro, Sweden

Pär Lodding Departments of Urology, Sahlgrenska University Hospital, Göteborg, Sweden

Timo Kylmälä Departments of Urology, Tampere University Hospital, Tampere, Finland

Per Lundmo Departments of Urology, St. Olavs University Hospital, Trondheim, Norway

Peter Klarskov Departments of Urology, Herlev Hospital, Copenhagen, Denmark

Teuvo L. J. Tammela Departments of Urology, Tampere University Hospital, Tampere, Finland

Ilker Tasdemir Urological Section, Stavanger University Hospital, Stavanger, Norway

Thomas Morris AstraZeneca, Macclesfield, UK

Jon Armstrong AstraZeneca, Macclesfield, UK

Your download is now in progress and you may close this window